Analysis of the Relationship between Type II Diabetes Mellitus and Parkinson’s Disease: A Systematic Review

Table 5

Protection of anti-Parkinson’s drugs in T2DM.

LEVODOPA	BROMOCRPTINE
No	Yes
Human trials: Cereda et al. [71], Rosati et al. [73]	Human trials Chamarthi et al. [74]; Roe et al. [75], Ghosh et al. [76], Gaziano et al. [77], Vinik et al. [78], Pijl et al. [79]
	Animal studies: Ezrokhi et al. [80], Luo et al. [81], Luo et al. [82], Cincotta et al. [83]